Seminar

22 November 2017: Seminar on Biosimilars & Competition Law

22 November 2017: Seminar on Biosimilars & Competition Law

22 November 2017: Seminar on Biosimilars & Competition Law

16.10.2017 NL law

On Wednesday 22 November 2017, Stibbe will organise a seminar on Biosimilars & Competition Law in Brussels. This seminar will be co-organized by competition lawyers from Stibbe and competition economists from CRA so as to cover both legal and economic angles relevant to this increasingly important field. 

Given the ever increasing economic significance of biologics in the pharmaceutical space – as well as signals from regulators that this field will come into focus shortly – it  is time to explore the implications of the competition rules for business behavior in this area. This includes a discussion of the following topics/questions: 

  • What can we expect from competition authorities in this space?
  • To what extent do the competition law principles developed for synthetic drugs apply to the biological space?
  • How does this play out in the context of life cycle management?  
  • What stance do authorities take in merger control cases involving biologics?
  • What about pricing strategies? Is there more reason for concern following cases like Aspen (EU) and Pfizer (UK)?

Our intention is to go beyond scratching the surface on these topics in order to provide guidance for pharmaceutical companies in an area which we feel is receiving insufficient attention in the competition law domain. 

For more information and to register, please send an email to: StibbeEvents@Stibbe.com.

A provisional program can be found below: 

  • 12:00 - 12:30: Registration
  • 12:30 - 12:45:  Introduction by chair - Stibbe/CRA
  • 12:45 - 13:15: Keynote speech by Paul Paul Csiszár, Director of "Basic Industries, Manufacturing and Agriculture", responsible for the Commission’s pharma unit
  • 13:15 - 13:45: Industry trends in biosimilars - Tim Wilsdon, CRA  
  • 13:45 - 14:30: Biologics in EU merger control: current status and likely issues in the future - Stibbe
  • 14:30 - 15:00: Break
  • 15:00 - 15:45: Competition law boundaries of life cycle management strategies: application to the biologics space - Stibbe
  • 15:45 - 16:30: Pricing practices & antitrust: law and economics - Raphaël De Coninck, CRA
  • 16:30 - 16: 45: Closing
  • 16:45 - 17:30: Drink

When: 22 November 2017 from 12.00 -17.30.

Where: Stibbe office: Central Plaza - Loksumstraat 25 Rue de Loxum - 1000 Brussels

stibbe_logo_background_01    logo - CRA

 

Team

Related news

05.08.2021 NL law
Court rules ACM can use accidental evidence found in dawn raids

Short Reads - While skimming through employees’ chat conversations and e-mails, it is not uncommon for competition authorities to stumble across other potential antitrust violations, separate from the initial scope of the search. Companies should realise that when this happens, a competition authority does not necessarily have to turn a blind eye to evidence lawfully collected during a dawn raid which points at a separate antitrust infringement, as confirmed by the preliminary relief court in The Hague.

Read more

05.08.2021 NL law
Netherlands FDI regime protecting national security is getting closer

Short Reads - On 30 June 2021, a legislative proposal introducing an investment screening on grounds of national security in the Netherlands was submitted to the House of Representatives. The proposal introduces an ex ante and ex post screening mechanism for investment activities related to vital providers or companies active in sensitive technology in the Netherlands. Although the regime is not yet effective, parties to a potential transaction should already account for the potential (including retroactive) effects of the regime.

Read more

05.08.2021 EU law
CJEU clarifies jurisdiction for follow-on damage claims

Short Reads - The Court of Justice of the European Union recently further clarified which courts within the EU have jurisdiction to hear follow-on damage claims. This can be either the court of the place where the claimant purchased a cartelized product, or where the claimant has its registered office (domicile), or at a centralized court designated by the EU member state for specific types of cases.

Read more